[cancerpage is a service of Alere]
 


[home]
[search the site]
[my cancerpage]
[ribbon project]
[stories and experiences]
[glossary of terms]
[journal of hope]
[comments]
[about us]
[policies and disclaimers]
[physician and service directories]

Hot Flashes May Help Guide Breast Cancer Risk Reduction

Last Updated: 2009-08-26 18:54:54 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Results of a study provide some indication that the presence of vasomotor symptoms may help in identifying women whose risk of invasive breast cancer is reduced by adoption of a low-fat diet.

"These findings," lead investigator Dr. Bette Caan told Reuters Health, "suggest that an easily obtainable clinical indicator such as the presence of hot flashes may be a useful tool for determining who may benefit from dietary recommendations for prevention of breast cancer."

Dr. Caan of Kaiser Permanente in Oakland, California, and colleagues came to this conclusion after studying data on almost 49,000 postmenopausal women taking part in a diet modification trial. Forty percent were randomized to a low-fat diet.

The study ran from 1993 to 1998 and the participants were queried semi-annually about a new diagnosis of breast cancer.

About 7%, or 3,375, reported hot flashes at baseline, the researchers report in a paper posted online August 17 in the Journal of Clinical Oncology.

Women with hot flashes who were assigned to the low-fat diet had a 35% risk reduction in breast cancer incidence compared to a 7% reduction in women who did not have hot flashes.

"The data suggest that women who are experiencing hot flashes or vasomotor symptoms may be more likely to reduce their risk of breast cancer by adopting a low-fat eating pattern," the study team reports.

Although the difference was not significant and was restricted to those with estrogen receptor-positive/progesterone receptor-positive tumors, the results, say the investigators, "are intriguing and warrant further investigation."

However, Dr. Caan stressed that "until we demonstrate this finding in other study populations, it is premature to use in a clinical setting."

Source:

  • J Clin Oncol 2009.


    "Reuters content is the intellectual property of Reuters Limited. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon."
  •  

     MedlinePlus is a resource for health information offered to the public by the US Government. The search box below will direct you to publicly available health information from the National Institutes of Health, the FDA and other government agencies.
    Search MEDLINEplus:
     

    MEDLINEplus en español

     
    We subscribe to the HONcode principles of the Health On the Net Foundation


    cancerpage.com 2000
    - 2009 . Please send your feedback, comments and suggestions to our staff. Read our policies and terms of service . cancerpage.com is a service of Alere® .
    © (2009) Inverness Medical. All Rights Reserved. Alere is a trademark of the Inverness Medical group of companies.